<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01596517</url>
  </required_header>
  <id_info>
    <org_study_id>AMC2003-0059</org_study_id>
    <nct_id>NCT01596517</nct_id>
  </id_info>
  <brief_title>Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C</brief_title>
  <official_title>Efficacy and Effectiveness of Combination Therapy With Pegylated Interferon Alfa-2a and Ribavirin in Korean Patients With Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and effectiveness of peginterferon
      alfa-2a and ribavirin therapy in Korean chronic hepatitis C patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A retrospective analysis of a prospective, multicenter, industry-sponsored, open-label,
      uncontrolled, community-based clinical trial of combination of peginterferon alfa-2a and
      ribavirin (Pegasys Expanded Access Program) conducted at 6 tertiary referral centers in Korea
      between 2003 and 2004 and a cohort of hepatitis C patients who were treated in a single
      tertiary referral hospital (Asan Medical Center, Seoul, Korea) between 2004 and 2008
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients achieving sustained virological response (SVR)</measure>
    <time_frame>at 24 weeks after cessation of treatment</time_frame>
    <description>SVR is defined as a documented undetectable serum HCV RNA by PCR at 24 weeks after cessation of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients achieving early virological response (EVR)</measure>
    <time_frame>at 12 weeks of treatment</time_frame>
    <description>EVR is defined as reduction of HCV RNA level by 2 log or more at 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of patients achieving complete EVR (cEVR)</measure>
    <time_frame>at 12 weeks of treatment</time_frame>
    <description>cEVR is defined as HCV RNA undetectable by PCR at 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients achieving end-of-treatment response (ETR)</measure>
    <time_frame>at week 48 for HCV genotype 1 and at week 24 for HCV genotype 2/3</time_frame>
    <description>ETR is defined as HCV RNA undetectable at the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">272</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Korean CHC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two CHC patient groups. One is CHC patients who are treated with combination of peginterferon alfa-2a and ribavirin in a prospective, multicenter, industry-sponsored, open-label, uncontrolled, community-based clinical trial (Pegasys Expanded Access Program) conducted at 6 tertiary referral centers in Korea between 2003 and 2004. Another is a cohort of hepatitis C patients who were treated in a single tertiary referral hospital (Asan Medical Center, Seoul, Korea) between 2004 and 2008.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a plus ribavirin for HCV genotype 1</intervention_name>
    <description>Patients with genotype 1: treatment with peginterferon α-2a (Roche, Basel, Switzerland) 180 μg/week and daily ribavirin dose of 1,000 mg (for patients with body weight &lt;75kg) or 1,200 mg (for patients with body weight ≥75kg) for 48 weeks.</description>
    <arm_group_label>Korean CHC</arm_group_label>
    <other_name>Pegasys</other_name>
    <other_name>Copegus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3</intervention_name>
    <description>Patients with genotype 2 or 3: treatment with peginterferon α-2a 180 μg/week and daily ribavirin dose of 800 mg for 24 weeks.</description>
    <arm_group_label>Korean CHC</arm_group_label>
    <other_name>Pegasys</other_name>
    <other_name>Copegus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: all of below

          -  adults aged 18-70 years

          -  serum anti-HCV antibody (+)

          -  HCV RNA detectable by PCR

          -  compensated liver disease (Child-Pugh class A)

        Exclusion Criteria: any of below

          -  HCV genotype other than 1, 2, or 3

          -  acute hepatitis C

          -  decompensated cirrhosis or hepatocellular carcinoma

          -  other liver disease such as hepatitis A or B, or autoimmune hepatitis

          -  HIV Ab(+)

          -  severe depression or other psychiatric disease

          -  previous organ transplantation

          -  absolute neutrophil count (ANC) &lt; 1,000 cells/mm3 or platelet count &lt; 75,000
             cells/mm3, or hemoglobin (Hb) &lt; 13 g/dL for men, &lt;12 g/dL for women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Suk Lim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2012</study_first_submitted>
  <study_first_submitted_qc>May 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2012</study_first_posted>
  <last_update_submitted>May 12, 2012</last_update_submitted>
  <last_update_submitted_qc>May 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Young-Suk Lim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

